ArticleBMC nephrology2026
Concurrent fabry disease and monoclonal gammopathy of renal significance: a case report.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFabry disease (FD) is a rare X-linked lysosomal storage disorder caused by genetic variant in the GLA gene, resulting in reduced α-galactosidase A (α-Gal A) activity and accumulation of glycosphingolipid substrates in multiple organs. Monoclonal gammopathy of renal significance (MGRS) refers to a group of disorders where monoclonal immunoglobulins produced by low-tumor-burden B-cell or plasma cell clones induce renal injury. There have never been any reports of FD and MGRS coexisting. CASE PRESENTATION: A 69-year-old male patient was hospitalized several times due to episodes of heart failure. His left ventricular enlargement had long been misdiagnosed as hypertrophic cardiomyopathy. One year after the initial heart failure episode, his renal function declined. Serum immunofixation electrophoresis detected IgG-λ monoclonal immunoglobulin, and renal biopsy confirmed proliferative glomerulonephritis with monoclonal immunoglobulin deposition (PGNMID). Further genetic testing revealed a heterozygous pathogenic genetic variant in the GLA gene (c.640-801G > A) and elevated Lyso-Gb3 levels, confirming the diagnosis of FD complicated by MGRS (PGNMID, IgG1-λ type). The patient's cardiac and renal functions have remained stable following enzyme replacement therapy and targeted clonal therapy.
conclusionClinically, patients who exhibit unexplained left ventricular hypertrophy together with renal impairment and monoclonal immunoglobulin deposition should be evaluated for the potential comorbidity of rare diseases. For the diagnosis of such complicated co-morbid disorders, renal biopsies and genetic testing are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.